US3906949A - Corneal bath - Google Patents

Corneal bath Download PDF

Info

Publication number
US3906949A
US3906949A US47570674A US3906949A US 3906949 A US3906949 A US 3906949A US 47570674 A US47570674 A US 47570674A US 3906949 A US3906949 A US 3906949A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
eye
hda
pressure
epinephrine
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Monte G Holland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H35/00Baths for specific parts of the body
    • A61H35/02Baths for specific parts of the body for the eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Abstract

A human eye whose intraocular pressure should, for medical reasons, be reduced, is treated with 6-hydroxydopamine to achieve sympathectomy of terminal axons of the eye, the sympathectomized eye is then treated with an adrenergic amine on a daily basis. The drop in intraocular pressure thus achieved is substantially greater than that procured by the treatment of the adrenergic amine alone.

Description

United States Patent 1191 Holland Sept. 23, 1975 CORNEAL BATH 1,388,621 8/1921 Um bsen 128/249 [7 Inventor: Monte G. a e Or a 1,437,435 12/1922 Maler 128/249 Primary ExaminerAldrich F. Medbery [73] Assignee. fiezearch Corporation, New York, Attorney, Agent, or Firm Omri M Behr [22] Filed: June 3, 1974 21 Appl.No.: 475,706 [57] ABSTRACT Related US, A li ti D t A human eye whose intraocular pressure should, for [62] Division of 249 814 May 3 1972 medical reasons, he reduced, is treated with 6- abandoned hydroxydopamine to achieve sympathectomy of terminal axons of the eye, the sympathectomized eye is [52 11.5. C1. 128/249 treated with an adrenergi'c mine on a daily basis- [51] Int. Cl A61m 7/00 The drop in intraocular Pressure thusiachieved is [58] Field of Search 128/248, 249 Stamially greater than that procured y the treatment of the adrenergic amine alone. [56] References Cited UNITED STATES PATENTS 2 Claims, 4 Drawing Figures 1,121,667 12/1914 Ross 128/249 US Patent Sept. 23,1975 3,906,949

CORNEAL BATH This is a division of application Ser. No. 249,814, filed May 3, 1972 and now abandoned.

The invention described herein was made in part in the course of work under a grant or award from the Department of Health, Education and Welfare.

FIELD OF THE INVENTION Lowering of intraocular pressure in human eyes.

DESCRIPTION OF THE PRIOR ART It is well known that the condition of the human eye known as glaucoma results from the presence of excess pressure within the eye. Such excess pressures cause disruption of the sight processes and in serious cases lead to total loss of the faculty of sight. In many cases the pressure may be modified by the use of an adrenergic amine. Such amines fall into two categories, those having the so-called alpha effect facilitate the outflow of fluids from the eye and those having the so-called beta effect restrict the inflow of fluids into the eye. The compound epinephrine is especially favored for the treatment of glaucoma since it has the useful property of being an alpha and beta adrenergic amine. By the continuous, that is to say, daily administration of, for example, epinephrine, by means of eyedrops, many cases of glaucoma may be managed and the sight of the patient maintained. There are, however, unfortunately certain types of glaucoma such as open angle glaucoma which will not respond adequately to this form of treat ment.

It is known (Homer, uber eine Form von Ptosis, Klin, Mb]. Augenheilk, 7, 193-198 (1869)) that lower intraocular pressures result from surgical sympathetic denervation. As a result of these observations attempts were made to utilize these findings in the control of glaucoma near the turn of the century, however, these attempts were abandoned not only because of the technical difficulties involved in the surgical procedure but also due to the lack of reliable results in controlling glaucoma.

Experiments in test animals have demonstrated that the application of 6-hydroxydopamine (hereinafter 6- I-IDA) causes a selective yet reversible degeneration of sympathetic terminal axons but does not affect sympathetic stem axons or other nerves. Thus, 6-HDA achieves chemically, and reversibly, the effect which was drastically and surgically achieved by Homer (supra). It should be noted however, that heretofore 6'I-IDA has not been utilizied in human eyes.

It has also been noted in certain test animals that fol lowing sympathetic denervation certain tissues have become extraordinarily sensitive to dilute solutions of epinephrine (Burn, J .H., Rand, M.J.; The cause of the supersensitivity of smooth muscle to noradrenaline after sympathetic degeneration, J. Physiol. 147, 135-143, 1959) (Trendelenburg, U., I. Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines, Pharmacol Rev. 18, 629-640, 1966). Again, these experiments do not concern the alpha and beta adrenergic effects in the human eye.

Heretofore certain experiments have been carried out applying 6-HDA to the corneas of rabbits and monkeys (Holland, MG. and Mims, J.L., III; Anterior Segment Chemical sympathectomy by 6- Hydroxydopamine. I. Effect on Intraocular Pressure and Facility of Outflow, Invent Ophthal; 10:120 (February) 1971)). In these studies epinephrine was not utilized but rather norepinephrine which has substantially solely alpha adrenergic properties and isoproterenol which has substantially solely beta adrenergic action so that the mechanisms of the effect might be more readily observed.

In the animal experiments it was found that 6-HDA caused a significant increase in fluid outflow, however, this effect did not persist .into the second week after treatment. In these experiments the occurrence sympathectomy of the axons was demonstrated by methods recognized in the art and reported in detail in said paper. The term supersensitization as used hereinbelow refers to the enhancement of any known physiological effect, thus as stated hereinabove, norepinephrine is shown to have an alpha adrenergic effect, that is to say, it facilitates fluid outflow in the eye.

In rabbits and monkeys whose eyes have been chemically sympathectomized with 6-HDA an immediate drop in the intraocular pressure was noted. However, this effect did not persist. Furthermore, neither the administration of norepinephrine or isoproterenol gave rise to further pressure drops in the treated eyes. Thus, it was concluded that chemical sympathectomy in these test animals using 6-HDA did not lead to supersensitization to norepinephrine or isoproterenol.

Thus, there is nothing in the art to suggest that 6-I-IDA would cause chemical sympathectomy in the human eye, and furthermore there is nothing in the art to suggest that if such chemical sympathectomy did occur the sympathectomized eyes would be supersensitized to the effect of alpha or beta adrenergic amines.

SUMMARY OF THE INVENTION The sympathetic terminal axons of human eyes, in particular, those suffering from excess intraocular pressure, are chemically sympathectomized by the application thereto of a dilute solution of 6-HDA. The 6-I-IDA may be administered by topical drops, by placing upon the cornea a hydrophilic contact lens previously soaked in a 6-I-IDA solution, by administering a solution upon the cornea by means of a specially designed corneal bath, or by subconjunctival injection of a solution of 6-I-IDA. The latter two modes being preferred and the last mode being especially preferred.

Following the treatment with 6-HDA, there is administered to the eye an alpha and beta adrenergically active amine such as epinephrine, or a combination of an alpha adrenergic amine and a beta adrenergic amine such as isoproterenol with norepinephrine. The use of epinephrine itself however being preferred. The administration of the adrenergic amine or amines continues to at least one month, preferably from one to three months, at the end of which time a further administration of 6-HDA by any of the foregoing methods is desirable.

Since the build-up of intraocular pressure is a continuous dysfunction of the eye, and visual faculties may only be maintained if the pressure is kept below an acceptable level in order to prevent deterioration of the optical nerve, it must be understood that the method of treatment set forth herein should be regarded as the treatment of a chronic condition, that is to say, it should be carried on continuously and that the one to three month pen'od should be regarded as a treatment cycle.

DESCRIPTION OF THE DRAWINGS FIG. 1 is a side-elevational view of a corneal bath of the present invention.

FIG. 2 is a top plan view of the bath of FIG. 1.

FIG. 3 is a bottom plan view of the bath of FIG. 1.

FIG. 4 is a side elevational sectional view of the bath of FIG. I viewed at 44.

The corneal bath utilized in the process of the present invention comprises substantially 4 segments; an eye contact segment 12 having a lower surface 14 shaped substantially to fit over the cornea of an eye, a lens portion 18, a lens holder portion into which lens 18 is set, said lens holder 20 having at least two orifices, 22 and 24 drilled therethrough, suitably but not critically in a plane substantially perpendicular to the plane of the lens. Inflow tube 26 is attached to, and into orifice 22 and outflow tube 28 is attached to orifice 24. The lens holder 18 is attached to eye contact portion 12 by means of connecting separator 30 whereby there is provided, when the device is placed upon the surface of the eye, an enclosed void between the surface of the eye and the lens set in the holder. In the operation of the device, a very slight vacuum is applied to one of the tubes 26 or 28, for example 28, and the liquid to be applied to the surface of the eye is drawn into the aforesaid void between the surface of the eye and the lens and its holder through the other tube. The device is emptied by opening one of the tubes to the atmosphere and applying a mild vacuum to the other tube.

The dimensions of the device are not critical provided that surface 14 is of such dimensions and shape as to be substantially in contact with the surface of the eye at all point, in any case, in such a manner that the fluids normally upon the surface of the eye would provide an effective seal between the surface of the eye and its periphery.

DESCRIPTION OF THE PREFERRED EMBODIMENTS In the preferred modifications of this invention sympathetic terminal axons of a human eye may be chemically sympathectomized by the application to said eye of an ophthalmologically acceptable aqueous solution of 6-hydroxydopamine. This application may be achieved by one of four embodiments. In all of these embodiments there is utilized an aqueous solution of 6-HDA. It is known that 6-HDA is extremely sensitive to oxidation, particularly in aqueous solution. The 6-I-IDA is usually commercially available as a crystalline powder. This powder is dissolved in deoxygenated distilled water containing a small amount of ophthalmologically acceptable antioxidant. Sodium metabisulfite has been found suitable as such antioxidant and is utilized in a strength of between 0.02 and 0.06, suitably about 0.045 molar. The pH of the solution is then adjusted to from about pH 6.2 to about pH 6.8, suitably to about pH 6.5 by addition of aqueous sodium hydrox ide, and the solution filtered through a millipore filter, a filter having a pore size of about 0.45 11. being preferred. All solutions should be immediately utilized care being taken to exclude air bubbles therefrom. Solutions should be totally colorless and solutions showing any signs of pink coloration must be discarded. The fluid should be discarded after use and the. crystalline powder should be stored under liquid nitrogen.

The solutions of 6-l-IDA may be used in the range of solutions at the upper end of this range tend to cause transient corneal punctate stromal opacities which usually cleared in between one to four weeks. On the other hand, solutions having a strength of less than 2% tended to give rise to incomplete sympathectomy. It has been found that a range of from about 2 to about 3% gives the most desirable results and a solution of 2.7% has been found to be especially suitable. It has further been found desirable though not critical, to prepare the eye to be treated with an ophthalmologically effective anesthetic such as proparacaine hydrochloride. In addition to the anesthetic efiects it has been found that this substance enhances the penetration of 6-HDA.

In one embodiment of the present invention, subsequent to anesthetization of the cornea two to three drops of a 1 to 10% solution of the 6-HDA as set forth above were applied to the cornea and the patients eyelids closed. It was found desirable to repeat this application from about two to about four times at intervals of from about 15 to about 45 minutes. Although this mode of administration has been found to be fairly effective, the degree of sympathectomy revealed by pupillary response to the hydroxyamphetamine test was not as great as that in other embodiments.

In a further embodiment of the invention a solution containing from 1 to 10% of 6-HDA was utilized as a bath in which a soft (i.e. hydrophilic) contact lens had been soaked for from about 15 min. to 2 hours. The soft contact lens is then placed upon the eye to be treated for a period of from about 1 to about 3 hours and then removed. While this method is more convetube 28 whereby 6-HDA solution is drawn in through the inlet tube 26. The degree of vacuum is not critical, and should be merely sufficient to draw the aqueous solution through the narrow inlet tube. That degree of vacuum created by placing a hypodermic syringe into tube 28 and withdrawing the plunger of said syringe would be substantially satisfactory.

While there may be utilized a solution of between 1 and 10% it is especially preferred to utilize a solution of from about 2 to about 2.7% w/w. The contact time may vary from about 15 minutes to about 1 hour, however 30 minutes appears to be the optimum period. Evaluation of this embodiment by standard means, demonstrates that complete sympathectomy has been achieved.

Yet another embodiment, which is the most preferred embodiment, comprises the subconjunctival injection of the 6-I-IDA solution. The advantage of this method is that it is rapid, and requires the use of extremely small quantities of 6-I-IDA solution. In this embodiment of the present invention a solution of 6-I-IDA, suitably a l to 4% solution is prepared, suitably in an air-free syringe capped with a millipore filter, and a small needle,suitably, to gage. There are administei'ed from between 0.l to about .Ig ml. of the solution, suitably about 0.2 .to 0.25 ml. of the solution by a series of injections around limbus of the eye. An evaluationof this mode shows that complete sympathectomy has occurred. I Subsequent to chemical sympathectomy, carried out by any of the foregoing methods, the eye-whose inter nal pressure is to;-be reducedcis' treated with adrenergic amines, suitably an alpha adrenergic amine, anda beta adrenergic amine preferably in combination either in the form of .an adrenergic. amine havingalpha activity together with an adrenergic amine having-beta-activity or, most preferably, an adrenergic amine combining both. activities such as epinephrine. There may be utilized ophthalmologically acceptable, aqueous solutions of epinephrine of between'l 'and'.3%,'suitably 1 or 2%;

isoproterenolof between 1 and 5%, suitably between 2 and 2.5%, and phenylephrine of between 5. to 10%, suitably about 10%; Especiallypreferred.amongthese adrenergic amines is epinephrine. .Heretoforeit has been known thatlepinephrine, especially when administered over long periods does cause a lowering of the intraocular pressure and upon prolonged usage does facilitate the outflow of fluid from the eye. However, in very severe cases of glaucoma neither the pressure drop nor the increase in outflow achieved by long term epinephrine therapy is sufficient to prevent irreversible damage .to the eye. t

In this portion of the invention, a solution of the adrenergic. amine suitably epinephrine is administered from one to four times a day for aperiod of 2 to 3 months. It has been observed that while a statistically significant loweririg of the intraocular pressure does occur, no increasein the facility of, the outflow is noted immediately after the first administration ofthe adrenergic amine. This pressure drop is not maintained in a statistically significant manner and continued application for at least one month is required in order to produce apressure drop and enhancement of facility of outflow which is statistically significant over control. It must be realized however that recourse must be had to statistical analysis since direct control experiments are not possible. Thus, while one eye of a patient suffering from glaucoma may be chemically sympathectomized and theother eye utilized as a control, the possibility exists that the untreated .eye may nevertheless become partially sympathectomized due to systemic absorption of the 6-HDA. Indeed, some evidence does exist that this does occur. .On the other hand, the response of totally untreated glaucomotose eyes would clearly be slightly different becausej-of the different chemical conditionand metabolic state of "the totally untreated control.

PHARMACOLOGICAL ANALYSIS AND RESULTS All patients tested were at the time, under maximum medical therapy,'that is to say," continuous treatment with epinephrine or thellik eQTests were carried out using a double control method. In Seven patients, one eye was chemically sympathectomized with 6-HDA and the' other eye was not treated with 6-HDA. In other patients no 6-I-IDA at'all was administered.-All results discussed below are statistical averages. Twenty-four patients constitute the sample upon which the statistical results are based. However, a total of 90 patients has been treated with substantially similar results.

Immediately following treatment with 6-HDA a statistically significant lowering of'intraocular pressure as well as a statistically significant increase in. facility ofoutflow was noted up to ,2 or 3 days after sympathectoniy. Repeatedltreatment with 6-HDA several times over a periodof 3 to 4' weeks, did not control intraocular pressure.

7 When sympathectomized eyes were treated with epinephrine solutions,'as low as 10% and tested one and a half hours aftertreatment, a statistically significant drop in intraocular pressure was noted, but no statistically significant increase in outflow facility was noted. Solutions up to a strength of 2% epinephrine were utilized in these tests. It is therefore concluded that this short-term effect of epinephrine upon 6-HDA sympathectomized eyes is due to,the beta adrenergic effect, that is to say, control of .fluid inflow rather than increase of facility of outflow.

Where 2% epinephrine was administered twice daily for a period of an average of 8l-days after sympathectomythe lowering of the intraocular pressure from an average of 39 millimeters Hg to an average of 19 millimeters Hg was noted, which result is highly significant statistically. The untreated eye of these patients when treated with epinephrine in a similar manner, also demonstrateda statistically significant decrease in intra0cular pressure, which however was substantially less than that in the sympathectomized eye and the difference in drops in pressure between the two eyes of the patient is also statistically significant. Hence, it must be concluded that the drop in pressure of the untreated eyes after prolonged epinephrine treatment must be due to partial sympathectomy caused by systemic absorption of thed6-HDA. In the same group of .patients in measurements carried, out after days of epinephrine treatment following 6-HDA sympathectomy, facility of outflow in the sympathectomized eyes was increased by 88%with high statistical significance, there was no statistically significantchange .in the facility of outflow in the eyes of these patients similarly treated with epinephrine but which had not been treated with 6-HDA. Hence, it may be concluded that the 6-HDA sympathetcomy coupled withlong'term epinephrine therapy significantly enhances the alpha adrenergic effect.

In most patients tested after approximately 100 days it was found desirable to repeat the sympathectomy in order to maintainthe enhanced pressure lowering ef- "fect of epinephrine or similar alpha or beta adrenergic effects achieved atthat time.

The foreg oing results are especially surprising since it has been noted that an alpha adrenergic drug, such as phen' ylephrine or norepinephrine, when applied per se to a sympathectomized eye does not produce immediate increased'facility of outflow. Similarly, epinephrine itself does not cause an immediate increase in facility' of outflow after chemical sympathectomy, although apressure drop is noted due, presumably, to the beta adrenergic effects of epinephrine. Hence, for increased outflow to occur it would appear that subsequent to chemical sympathectomy, treatment with an adrenergically active compound exhibiting alpha activity is required, for a substantial period of time in order to achieve a greater alpha adrenergic effect on outflow facility than is observed in unsympathectomized glaucomatous eyes.

EXAMPLE I EXAMPLE II Soft Contact Lens Application A soft contact lens was soaked in a solution of 6-HDA for three-fourths hours. The saturated soft contact lens was placed on the patients left cornea for 1 hour.

There was dilatation of both pupils as tested with hydroxy-amphetamine. The untreated eye showed greater dilatation than the 6-HDA treated eye indicating some but incomplete sympathectomy in the treated eye.

EXAMPLE Ill Corneal Bath Application A corneal bath of the design described hereinabove was applied to the right eye of the patient, filled with 6-HDA (4% aq.) and left in contact with the eye for one hour.

Following treatment, there was subconjunctival edema and some corneal edema. The hydroxyamphetamine test showed no pupillary dilatation in the 6-HDA treated eye.

Prior to sympathectomy this patient had an intraocular pressure of 38 mm. Hg and an outflow of 0.09 .tl/mmHg/min under treatment with 0.1 ml. twice per day of 2% epinephrine.

After sympathectomy, the above sympathectomized eye was treated for 60 days with 0.1 ml. of epinephrine (2%) applied 3 times per day. At the end of this time intraocular pressure was 19 mm Hg and outflow was 0.24 uL/mm Hg/min.

EXAMPLE 1V Corneal Bath Application 2.7% 6-HDA was applied to the patients left eye for 30 minutes, according to the method of Example III.

There was a slight superficial punctate keratitis and some conjunctival congestion. The hydroxyamphetamine test showed an absence of dilatation of the pupil indicating a complete chemical sympathectomy.

Prior to sympathectomy this patient had an intraocular pressure of 42 mm. Hg and an outflow of 0.125 ul/mm Hg/min under treatment with 0.1 ml twice per day of 2% epinephrine.

After sympathectomy, the above sympathectomized eye was treated for 75 days with 0.1 ml. of epinephrine (2%) applied twice per day. At the end of this time intraocular pressure was 20 mm. Hg and outflow was 0.36 pal/mm Hg/min.

EXAMPLE V Subconjunctival Injection 0.2 ml. of 6-HDA solution (2% aq.) was injected around the limbus in both eyes.

After the injections, there was redness of the conjuncitva but the patient evidenced no discomfort. Thirty minutes later, the redness began to subside and moderate redness remained which persisted for 2 to 3 days. The intraocular pressure before treatment were 50 mm. Hg in both eyes. One day after treatment the pressures were measured at 20 mm. Hg (right eye) and 18 mm. Hg (left eye), respctively. The patient was placed on 2% epinephrine (0.1 ml.) thrice a day with pilocarpine (6%, 0.1 ml.) four times per day. One month after treatment, the pressures were 19 and 20 mm. Hg respectively. Two months later, they were 20 mm. Hg in both eyes, and five months later, they were 26 mm. Hg. in both eyes. The patient was retreated at this time. Pressures again fell to 20 mm. Hg. on topical epinephrine 2% (0.1 ml.) thrice a day plus pilocarpine 6% (0.1 ml.) four times a day.

Prior to sympathectomy this patient had an intraocular pressure of 50 mm. Hg. under treatment with 0.1 ml two times per day of 2% epinephrine, together with 0.1 ml 2 times a day of 0.25% phospholine.

EXAMPLE VI Drug Preparation The 6-HDA was supplied (by the Regis Chemical Company, Chicago) as a crystalline powder which had to be protected from exposure to oxygen because of its strong oxidation potential. The 6-HDA was dissolved in deoxygenated distilled water with 0.045 molar sodium metabisulfite added as an antioxidant. The pH was adjusted to 6.5 by sodium hydroxide, and the solution was filtered through a 0.45 p. millipore filter. All drug solutions were made immediately prior to administration. Care was taken to exclude air bubbles from the solution. Oxidation could be detected by pink discoloration of the fluid and only solutions which were clear, colorless, and therefore free of oxidation were used. After use, the fluid was discarded and the crystalline powder was stored under liquid nitrogen for subsequent use.

I claim:

1. A corneal bath comprising:

a lens a substantially cylindrical annular lens holder,

wherein the outer circumference of the lens is sealed into the inner circumference of said annular .lens holder, a cup shaped corneal eye contact portion, and

means for defining a corneal bath portion comprising a connecting and separating portion between said eye contact portion and said lens holder portion and at least two access means in said lens holder communicating with said bath portion for introducing liquid and gaseous fluids into and removing said fluids from both portions of said corneal bath.

2. A corneal bath according to claim 1 wherein the eye contact portion is in the shape of a hollow frustrum of a cone the upper portion of said frustrum being joined to said connecting means, and wherein said access means comprise aperatures consisting of substantially diametrically spaced upstanding tubes mounted in the lens holder.

Claims (2)

1. A corneal bath comprising: a lens a substantially cylindrical annular lens holder, wherein the outer circumference of the lens is sealed into the inner circumference of said annular lens holder, a cup shaped corneal eye contact portion, and means for defining a corneal bath portion comprising a connecting and separating portion between said eye contact portion and said lens holder portion and at least two access means in said lens holder communicating with said bath portion for introducing liquid and gaseous fluids into and removing said fluids from both portions of said corneal bath.
2. A corneal bath according to claim 1 wherein the eye contact portion is in the shape of a hollow frustrum of a cone the upper portion of said frustrum being joined to said connecting means, and wherein said access means comprise aperatures consisting of substantially diametrically spaced upstanding tubes mounted in the lens holder.
US3906949A 1972-05-03 1974-06-03 Corneal bath Expired - Lifetime US3906949A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US3849577A US3849577A (en) 1972-05-03 1972-05-03 Method of reducing intraocular pressure in human eyes
US3906949A US3906949A (en) 1972-05-03 1974-06-03 Corneal bath

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3906949A US3906949A (en) 1972-05-03 1974-06-03 Corneal bath

Publications (1)

Publication Number Publication Date
US3906949A true US3906949A (en) 1975-09-23

Family

ID=26940372

Family Applications (1)

Application Number Title Priority Date Filing Date
US3906949A Expired - Lifetime US3906949A (en) 1972-05-03 1974-06-03 Corneal bath

Country Status (1)

Country Link
US (1) US3906949A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
US7883031B2 (en) 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US8684980B2 (en) 2010-07-15 2014-04-01 Corinthian Ophthalmic, Inc. Drop generating device
US20140135716A1 (en) * 2011-06-30 2014-05-15 Sanofi-Aventis Deutschland Gmbh Intraocular Medicament Delivery Device
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US9087145B2 (en) 2010-07-15 2015-07-21 Eyenovia, Inc. Ophthalmic drug delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1121667A (en) * 1913-07-02 1914-12-22 Justin E Ross Eye-bath.
US1388621A (en) * 1919-09-08 1921-08-23 Umbsen Mfg Corp Device for treating the eyes
US1437435A (en) * 1921-01-11 1922-12-05 Maier Friedrich Eye-washing device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1121667A (en) * 1913-07-02 1914-12-22 Justin E Ross Eye-bath.
US1388621A (en) * 1919-09-08 1921-08-23 Umbsen Mfg Corp Device for treating the eyes
US1437435A (en) * 1921-01-11 1922-12-05 Maier Friedrich Eye-washing device

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
US7883031B2 (en) 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
US8936021B2 (en) 2003-05-20 2015-01-20 Optimyst Systems, Inc. Ophthalmic fluid delivery system
US8684980B2 (en) 2010-07-15 2014-04-01 Corinthian Ophthalmic, Inc. Drop generating device
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US9087145B2 (en) 2010-07-15 2015-07-21 Eyenovia, Inc. Ophthalmic drug delivery
US20140135716A1 (en) * 2011-06-30 2014-05-15 Sanofi-Aventis Deutschland Gmbh Intraocular Medicament Delivery Device
US9907694B2 (en) * 2011-06-30 2018-03-06 Sanofi-Aventis Deutschland Gmbh Intraocular medicament delivery device

Similar Documents

Publication Publication Date Title
Becker et al. Topical epinephrine in glaucoma suspects
ADAMS et al. Anaesthesia and intraocular pressure
Phillips et al. Propranolol as ocular hypotensive agent.
Kolker et al. Epinephrine maculopathy
Shaffer et al. Anticholinesterase drugs and cataracts
Chandler Long-Term Results in Glaucoma Therapy*: The Sanford R. Gifford Lecture
BECKER et al. Topical epinephrine therapy of open-angle glaucoma
Urrets-Zavaliaa Fixed, Dilated Pupil, Iris Atrophy and Secondary Glaucoma*: A Distinct Clinical Entity Following Penetrating Keratoplasty in Keratoconus
Brubaker Flow of aqueous humor in humans [The Friedenwald Lecture]
Zimmerman et al. Timolol: dose response and duration of action
Abrams et al. ALO 2145 (p-Aminoclonidine Hydrochloride)
Robin et al. Following Argon Laser Trabeculoplasty
Robin et al. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy
US3870791A (en) Solid state ophthalmic medication delivery method
Iliff Treatment of the vitreous-tug syndrome
US5869468A (en) Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs
US5462739A (en) Microdelivery device and method for enhanced drug administration to the eye
US5510101A (en) Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US4981871A (en) Treatment of ocular hypertension with class I calcium channel blocking agents
Hollenhorst et al. Unilateral blindness occurring during anesthesia for neurosurgical operations
Brown et al. Neurotrophic and anhidrotic keratopathy treated with substance P and insulinlike growth factor 1
Blok et al. Use of the megasoft bandage lens for treatment of complications after trabeculectomy
Radius et al. A new drug for management of chronic simple glaucoma
US4476140A (en) Composition and method for treatment of glaucoma
US3845201A (en) Solid state ophthalmic medication delivery method